146 related articles for article (PubMed ID: 31841566)
1. New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation.
Schwertheim S; Theurer S; Jastrow H; Herold T; Ting S; Westerwick D; Bertram S; Schaefer CM; Kälsch J; Baba HA; Schmid KW
PLoS One; 2019; 14(12):e0226199. PubMed ID: 31841566
[TBL] [Abstract][Full Text] [Related]
2. Intranuclear inclusions in hepatocellular carcinoma contain autophagy-associated proteins and correlate with prolonged survival.
Schwertheim S; Westerwick D; Jastrow H; Theurer S; Schaefer CM; Kälsch J; Möllmann D; Schlattjan M; Wedemeyer H; Schmid KW; Baba HA
J Pathol Clin Res; 2019 Jul; 5(3):164-176. PubMed ID: 30859721
[TBL] [Abstract][Full Text] [Related]
3. Characterization of two types of intranuclear hepatocellular inclusions in NAFLD.
Schwertheim S; Kälsch J; Jastrow H; Schaefer CM; Theurer S; Ting S; Canbay A; Wedemeyer H; Schmid KW; Baba HA
Sci Rep; 2020 Oct; 10(1):16533. PubMed ID: 33024131
[TBL] [Abstract][Full Text] [Related]
4. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
Bommarito A; Richiusa P; Carissimi E; Pizzolanti G; Rodolico V; Zito G; Criscimanna A; Di Blasi F; Pitrone M; Zerilli M; Amato MC; Spinelli G; Carina V; Modica G; Latteri MA; Galluzzo A; Giordano C
Endocr Relat Cancer; 2011 Dec; 18(6):669-85. PubMed ID: 21903858
[TBL] [Abstract][Full Text] [Related]
5. Computer-assisted image analysis of cytological specimens clarify the correlation between nuclear size and intranuclear cytoplasmic inclusions regardless of BRAFV600E mutation in papillary thyroid carcinoma.
Suzuki M; Moriya S; Kobayashi S; Nishijima Y; Fujii T; Ikota H; Yokoo H; Saio M
Cytopathology; 2021 Nov; 32(6):718-731. PubMed ID: 34159645
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, surgical approach, BRAFV600E mutation and sodium iodine symporter expression in pediatric patients with thyroid carcinoma.
Castro P; Patiño E; Fierro F; Rojas C; Buitrago G; Olaya N
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1457-1463. PubMed ID: 33031052
[TBL] [Abstract][Full Text] [Related]
7. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
9. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
10. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
Pyo JS; Sohn JH; Kang G
Endocr Pathol; 2015 Sep; 26(3):211-7. PubMed ID: 25957797
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
12. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
13. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology.
Singarayer R; Mete O; Perrier L; Thabane L; Asa SL; Van Uum S; Ezzat S; Goldstein DP; Sawka AM
Endocr Pathol; 2019 Sep; 30(3):201-218. PubMed ID: 31300997
[TBL] [Abstract][Full Text] [Related]
16. Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer.
Kim HM; Kim ES; Koo JS
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257096
[TBL] [Abstract][Full Text] [Related]
17. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer.
Song YS; Yoo SK; Kim HH; Jung G; Oh AR; Cha JY; Kim SJ; Cho SW; Lee KE; Seo JS; Park YJ
Endocr Relat Cancer; 2019 Jun; 26(6):629-641. PubMed ID: 30999281
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
19. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.
Elisei R; Viola D; Torregrossa L; Giannini R; Romei C; Ugolini C; Molinaro E; Agate L; Biagini A; Lupi C; Valerio L; Materazzi G; Miccoli P; Piaggi P; Pinchera A; Vitti P; Basolo F
J Clin Endocrinol Metab; 2012 Dec; 97(12):4390-8. PubMed ID: 23066120
[TBL] [Abstract][Full Text] [Related]
20. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
